Luisa Hector
Stock Analyst at Berenberg Bank
(3.69)
# 2,091
Out of 5,065 analysts
298
Total ratings
56.7%
Success rate
5.1%
Average return
Main Sectors:
Stocks Rated by Luisa Hector
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| LON: AZN AstraZeneca PLC | Reiterated: Buy | 15,000p | 12,400p | +20.97% | 76 | Oct 16, 2026 | |
| SWX: ROP Roche Holding AG | Reiterated: Hold | CHF 350.00 | CHF 380.10 | -7.92% | 55 | Oct 7, 2026 | |
| EPA: SAN Sanofi | Reiterated: Buy | €105.00 | €71.01 | +47.87% | 54 | Oct 5, 2026 | |
| ABBV AbbVie | Reiterated: Buy | $275 | $282.68 | -2.72% | 20 | Sep 10, 2026 | |
| MRK Merck & Co. | Reiterated: Hold | $125 → $127 | $143.63 | -11.58% | 35 | Aug 5, 2026 | |
| SWX: NOVN Novartis AG | Rated: Hold | CHF 92.00 → CHF 110.00 | CHF 124.20 | -11.43% | 4 | Mar 6, 2026 | |
| LON: BTRW Barratt Redrow plc | Reiterated: Hold | 414p | 309p | +33.94% | 1 | Feb 11, 2026 | |
| LON: GSK GSK plc | Reiterated: Hold | 1,660p | 1,855p | -10.51% | 7 | Jan 6, 2026 | |
| SNY Sanofi | Reiterated: Buy | $63 → $67 | $39.57 | n/a | 11 | May 16, 2025 | |
| BMY Bristol-Myers Squibb Company | Reiterated: Hold | $55 → $60 | $58.83 | n/a | 18 | Dec 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | €197.00 | €144.35 | n/a | 13 | Feb 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $43 | $29.44 | n/a | 1 | Jun 14, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | €77.50 | €43.40 | n/a | 1 | Sep 11, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | n/a | $12.12 | n/a | 2 | Sep 15, 2016 |
AstraZeneca PLC
Oct 16, 2026
Reiterated: Buy
Price Target: 15,000p
Current: 12,400p
Upside: +20.97%
Roche Holding AG
Oct 7, 2026
Reiterated: Hold
Price Target: CHF 350.00
Current: CHF 380.10
Upside: -7.92%
Sanofi
Oct 5, 2026
Reiterated: Buy
Price Target: €105.00
Current: €71.01
Upside: +47.87%
AbbVie
Sep 10, 2026
Reiterated: Buy
Price Target: $275
Current: $282.68
Upside: -2.72%
Merck & Co.
Aug 5, 2026
Reiterated: Hold
Price Target: $125 → $127
Current: $143.63
Upside: -11.58%
Novartis AG
Mar 6, 2026
Rated: Hold
Price Target: CHF 92.00 → CHF 110.00
Current: CHF 124.20
Upside: -11.43%
Barratt Redrow plc
Feb 11, 2026
Reiterated: Hold
Price Target: 414p
Current: 309p
Upside: +33.94%
GSK plc
Jan 6, 2026
Reiterated: Hold
Price Target: 1,660p
Current: 1,855p
Upside: -10.51%
Sanofi
May 16, 2025
Reiterated: Buy
Price Target: $63 → $67
Current: $39.57
Upside: n/a
Bristol-Myers Squibb Company
Dec 10, 2024
Reiterated: Hold
Price Target: $55 → $60
Current: $58.83
Upside: n/a
Feb 10, 2022
Reiterated: Hold
Price Target: €197.00
Current: €144.35
Upside: n/a
Jun 14, 2021
Reiterated: Hold
Price Target: $43
Current: $29.44
Upside: n/a
Sep 11, 2018
Reiterated: Hold
Price Target: €77.50
Current: €43.40
Upside: n/a
Sep 15, 2016
Reiterated: Hold
Price Target: n/a
Current: $12.12
Upside: n/a